Transforming vaccine development

Steve Black; David E Bloom; David C Kaslow; Simone Pecetta; Rino Rappuoli

doi:10.1016/j.smim.2020.101413

Transforming vaccine development

Semin Immunol. 2020 Aug:50:101413. doi: 10.1016/j.smim.2020.101413. Epub 2020 Oct 28.

Authors

Steve Black¹, David E Bloom², David C Kaslow³, Simone Pecetta⁴, Rino Rappuoli⁵

Affiliations

¹ Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
² Harvard T.H. Chan School of Public Health, Harvard University, Boston MA 02115, USA.
³ PATH, Seattle WA 98121, USA.
⁴ GSK, 53100 Siena, Italy.
⁵ GSK, 53100 Siena, Italy; Imperial College London, London SW7 2AZ, UK. Electronic address: rino.r.rappuoli@gsk.com.

Abstract

The urgency to develop vaccines against Covid-19 is putting pressure on the long and expensive development timelines that are normally required for development of lifesaving vaccines. There is a unique opportunity to take advantage of new technologies, the smart and flexible design of clinical trials, and evolving regulatory science to speed up vaccine development against Covid-19 and transform vaccine development altogether.

Keywords: Adjuvants; COVID-19; Human genetics; Machine learning; Platform technologies; Real world evidence; Regulatory convergence; Smart clinical trials; Systems biology; Vaccine; Vaccine development; Vaccine discovery; Vaccines safety.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / therapeutic use*
Drug Approval*
Humans
Machine Learning
Public Health / methods
SARS-CoV-2 / immunology
Systems Biology / methods*
Vaccinology / methods

Substances

COVID-19 Vaccines